P53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia

World Journal of Gastroenterology

Volumn 17, Issue 19, 2011, Pages 2417-2423

  Hamouda, Hala E ^a   Zakaria, Soha S ^a   Ismail, Saber A ^a   Khedr, Mahmoud A ^a   Mayah, Wael W ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Advanced oxidation protein products; Metallothionein; Reduced glutathione; Ulcerative colitis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANTIBODY; BIOLOGICAL MARKER; GLUTATHIONE; METALLOTHIONEIN; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DYSPLASIA; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; ULCERATIVE COLITIS;

EID: 79957832909     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i19.2417     Document Type: Article

References (42)

1. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-281, vii
2. Risques RA, Rabinovitch PS, Brentnall TA. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr Opin Gastroenterol 2006; 22: 382-390
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535
4. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021
5. Fujii S, Katsumata D, Fujimori T. Limits of diagnosis and molecular markers for early detection of ulcerative colitisassociated colorectal neoplasia. Digestion 2008; 77 Suppl 1: 2-12
6. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 2008; 204: 511-524
7. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Karakukcu C, Ustdal M. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 2006; 24: 307-311
8. Wykretowicz A, Adamska K, Krauze T, Guzik P, Szczepanik A, Rutkowska A, Wysoki H. The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults. Free Radic Res 2007; 41: 645-649
9. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
10. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseasesclinical chemistry and genetic background. Mutat Res 2005; 579: 37-46
11. Peng KF, Wu XF, Zhao HW, Sun Y. Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Chin Med J (Engl) 2006; 119: 1088-1093
12. Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W. Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 2003; 48: 2083-2090
13. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002; 59: 627-647
14. Roesijadi G. Metal transfer as a mechanism for metallothionein- mediated metal detoxification. Cell Mol Biol (Noisy-legrand) 2000; 46: 393-405
15. Cioffi M, Riegler G, Vietri MT, Pilla P, Caserta L, Carratù R, Sica V, Molinari AM. Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm Bowel Dis 2004; 10: 606-611
16. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 1996; 17: 354-356
17. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 1777-1788
18. El-Sayed ZA, Farag DH, Eissa S. Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pediatr Allergy Immunol 2003; 14: 229-233
19. Coomber D, Hawkins NJ, Clark M, Meagher A, Ward RL. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 1996; 122: 757-762
20. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560
21. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968
22. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25: 192-205
23. Cousins RJ. Measurement of human metallothionein by enzyme-linked immunosorbent assay. Methods Enzymol 1991; 205: 131-140
24. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16: 3158-3168
25. Fricke H, Urban S, Noehl N, Folwaczny C. Serum p53 antibodies in patients with chronic inflammatory bowel disease. Gut 1998; 42: 899
26. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 24: 353-362
27. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash GS. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1020-1030
28. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859-861
29. Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L, Gamian A. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 2008; 14: 794-802
30. Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci 2008; 21: 286-289
31. Avinash SS, Anitha M, Vinodchandran, Rao GM, Sudha K, Shetty BV. Advanced oxidation protein products and total antioxidant activity in colorectal carcinoma. Indian J Physiol Pharmacol 2009; 53: 370-374
32. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015
33. Holmes EW, Yong SL, Eiznhamer D, Keshavarzian A. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci 1998; 43: 1088-1095
34. Saygili EI, Akcay T, Konukoglu D, Papilla C. Glutathione and glutathione-related enzymes in colorectal cancer patients. J Toxicol Environ Health A 2003; 66: 411-415
35. Scibior D, Skrzycki M, Podsiad M, Czeczot H. Glutathione level and glutathione-dependent enzyme activities in blood serum of patients with gastrointestinal tract tumors. Clin Biochem 2008; 41: 852-858
36. Brüwer M, Schmid KW, Metz KA, Krieglstein CF, Senninger N, Schürmann G. Increased expression of metallothionein in inflammatory bowel disease. Inflamm Res 2001; 50: 289-293
37. Waeytens A, De Vos M, Laukens D. Evidence for a potential role of metallothioneins in inflammatory bowel diseases. Mediators Inflamm 2009; 2009: 729172
38. Bruewer M, Schmid KW, Krieglstein CF, Senninger N, Schuermann G. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J Surg 2002; 26: 726-731
39. Kim HJ, Chang SK. p53 mutation in patients with ulcerative colitis in rectal biopsy. Korean J Intern Med 1998; 13: 110-116
40. Yoshizawa S, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Mukai M, Fujita T, Kawakami Y, Hibi T. Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis 2007; 13: 865-873
41. Kulic A, Sirotkovic-Skerlev M, Jelisavac-Cosic S, Herceg D, Kovac Z, Vrbanec D. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients. Med Oncol 2010; 27: 887-893
42. Radovic S, Vukobrat-Bijedic Z, Selak I, Babic M. Expression of p53, bcl-2, and Ki-67 proteins in the inflammatory regenerative and dysplastic epithelial lesions of flat colonic mucosa. Bosn J Basic Med Sci 2006; 6: 39-45